RIV Capital Inc.

RIV.CN · Canadian Securities Exchange · CAD

0,10CAD

−0,005 (−4,76 %)Stand 19. Dez., 17:55

Vortag 0,105

Kennzahlen

Eröffnung
–
Vortag
0,105
Tagesspanne
0,10 – 0,10
52 Wochen
0,10 – 0,23
Ø Volumen
45.692
Börsenwert
13,7 Mio. CAD
KGV
-0,1
Gewinn je Aktie (TTM)
-0,92
Dividendenrendite
0,0 %
Beta
0,6
Nächste Zahlen
–

Finanzen

USDFY 2022FY 2021FY 2020FY 2019FY 2018
Umsatz6,81 Mio.13,43 Mio.10,1 Mio.8,13 Mio.3,16 Mio.
Herstellungskosten4,37 Mio.53,66 Mio.53,63 Mio.00
Bruttogewinn2,44 Mio.−40,23 Mio.−43,53 Mio.4,87 Mio.54,78 Mio.
Forschung und Entwicklung0−21−900
Vertrieb und Verwaltung18,32 Mio.7,76 Mio.6,09 Mio.13,02 Mio.22,81 Mio.
Operatives Ergebnis−11,82 Mio.−24,38 Mio.−24,64 Mio.8,03 Mio.46,81 Mio.
EBITDA−44,96 Mio.−24,16 Mio.−24,46 Mio.10,36 Mio.72,39 Mio.
Nettogewinn−179,26 Mio.−42,21 Mio.−106,01 Mio.−28,59 Mio.2,93 Mio.
Gewinn je Aktie (verwässert)-1,09-0,30-0,75-0,150,02

Bewertung

Letzte 12 Monate

KGV
-0,1
Kurs-Umsatz-Verhältnis
1,4
Kurs-Buchwert-Verhältnis
0,1
PEG
0,0
Bruttomarge
35,8 %
Operative Marge
−173,6 %
Nettomarge
−2.633,5 %
Verschuldungsgrad
1,0
EV/EBITDA
-0,9
Eigenkapitalrendite
−96,0 %
Kapitalrendite (ROIC)
−2,0 %
Free-Cashflow-Rendite
−290,7 %
FY 2022FY 2021FY 2020FY 2019FY 2018
Bruttomarge35,8 %−299,5 %−431,1 %59,9 %1.731,0 %
Operative Marge−173,6 %−181,5 %−244,0 %98,8 %1.479,1 %
Nettomarge−2.633,5 %−314,3 %−1.049,8 %−351,7 %92,7 %
KGV-0,1-4,8-3,1-6,0222,7
Kurs-Umsatz-Verhältnis2,915,432,820,9206,9
Kurs-Buchwert-Verhältnis0,20,81,30,82,1
Verschuldungsgrad1,00,30,00,00,0
Liquidität 3. Grades83,783,761,813,114,9
Dividendenrendite0,0 %0,0 %0,0 %0,0 %0,0 %
Unternehmenswert52,54 Mio.−31,67 Mio.230,13 Mio.137 Mio.577,2 Mio.
EV/EBITDA-1,21,3-9,413,28,0
Eigenkapitalrendite−164,7 %−15,9 %−43,0 %−13,6 %1,0 %
Kapitalrendite (ROIC)−2,0 %−5,6 %−9,3 %2,2 %12,9 %
Free-Cashflow-Rendite−141,7 %−10,5 %−2,0 %−3,2 %−0,3 %

Wachstum

FY 2022FY 2021FY 2020FY 2019FY 2018
Umsatz−49,3 %+33,0 %+24,2 %+156,9 %−95,5 %
Bruttogewinn+106,1 %+7,6 %−994,4 %−91,1 %−22,5 %
Operatives Ergebnis+51,5 %+1,1 %−407,0 %−82,9 %−22,5 %
Nettogewinn−324,7 %+60,2 %−270,8 %−1.074,4 %+6.794,8 %
Gewinn je Aktie−263,3 %+60,0 %−400,0 %−952,3 %+4.500,0 %
Freier Cashflow−28,4 %−234,4 %−20,3 %−174,0 %−22.240,3 %
Dividende je Aktie0,0 %0,0 %0,0 %0,0 %0,0 %

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Nov. 2024Aug. 2024Apr. 2024März 2024Nov. 2023Aug. 2023Juni 2023März 2023
Gewinn je Aktie · Erwartet–––––––-0,02
Gewinn je Aktie · Tatsächlich-0,62-0,08-0,05-0,48-0,07-0,09-0,20-0,08
Abweichung–––––––−287,38 %
Umsatz · Tatsächlich6,59 Mio.5,18 Mio.2,9 Mio.2,81 Mio.3,12 Mio.2,37 Mio.2,29 Mio.2,56 Mio.

Dividenden und Splits

Keine Dividenden gezahlt.

Aktiensplits

  • 20. Sept. 201837:1000

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

–

Vergleichbare Unternehmen

Über das Unternehmen

RIV Capital Inc., formerly known as Canopy Rivers Inc., operates as a venture capital firm with a versatile investment approach. While open to opportunities across all company stages, from initial seed funding through commercialization, its primary focus is on Series A through C financing rounds. The firm's strategic interest is firmly rooted in the burgeoning cannabis sector, actively seeking out promising marijuana-related businesses and adjacent industries. Its comprehensive investment scope encompasses a wide array of areas: Agriculture and food sciences: Spanning plant, soil, food, animal, and environmental science. Production: Including diverse cultivation methods such as indoor, greenhouse, outdoor, and nursery, alongside fermentation. Processing: Involving harvesting, extraction, purification, packaging, food and beverage processing, and laboratory testing services. Pharmaceuticals and biotechnology: Covering drug discovery and development, various delivery methods (e.g., pills, soft gels, tinctures), biosynthetic derived cannabinoids, medical devices (e.g., inhalers), and lab equipment. Technology and consumer goods: Such as software and data, specialized hardware, consumer products and accessories (e.g., edibles, beverages, inhalables, cosmetics, cannabis consumption tools), and wellness products. Market access: Including retail and distribution channels (licensed brick-and-mortar stores, pharmacies, online marketplaces, delivery services), and media and content creation. Furthermore, specific product categories of interest include beverages, capsules, concentrates, edibles, dry flower/pre-rolls, vaporizers and associated hardware, pet products, and topicals. RIV Capital actively pursues investment prospects on a global scale. While check sizes have historically ranged from CA$1 million (approximately $0.71 million USD) to CA$40 million (around $28.45 million USD), the firm typically invests between CA$5 million (roughly $3.6 million USD) and CA$10 million (approximately $7.1 million USD). The firm generally seeks to acquire minority ownership stakes and employs a flexible array of investment instruments, including debt financing, preferred and common equity, and production-linked royalties. RIV Capital Inc. was established in 2017 and is headquartered in Toronto, Canada.

Führung

  • Matthew Jonathon MundyChief Strategy Officer, General Counsel & Corporate Secretary
  • Edward James Cirillo LucarelliChief Financial Officer
  • David E. VautrinChief Retail Officer & Interim Chief Executive Officer
  • Peter HatziioannouCo-Founder & Advisor
  • Sean McNultyCo-Founder & Advisor
CEO
David E. Vautrin
Mitarbeitende
94
Hauptsitz
Toronto, ON, CA
Sektor
Healthcare
Branche
Drug Manufacturers - Specialty & Generic
Börsengang
20. Sept. 2018

Nachrichten

Gerade keine Nachrichten zu diesem Unternehmen.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.